Extending patents for pharmaceutical formulations is a topic which attracts much debate. In Europe, patentees can obtain supplementary protection certificates where they have experienced significant regulatory delays in getting their patented pharmaceutical products onto the market. Charlotte Teall at Forresters looks into forthcoming changes and how they are likely to increase the hurdles to the regulation of medical devices in Europe.